Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Baird Medical Investment Holdings Limited (BDMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: BDMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -20.62% | Avg. Invested days 65 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 234.17M USD | Price to earnings Ratio 18.4 | 1Y Target Price - |
Price to earnings Ratio 18.4 | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.7 | 52 Weeks Range 1.05 - 12.75 | Updated Date 06/3/2025 |
52 Weeks Range 1.05 - 12.75 | Updated Date 06/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.35 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 37.96% | Operating Margin (TTM) 38.74% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE 18.4 | Forward PE - | Enterprise Value 248186805 | Price to Sales(TTM) 7.09 |
Enterprise Value 248186805 | Price to Sales(TTM) 7.09 | ||
Enterprise Value to Revenue 7.51 | Enterprise Value to EBITDA 15.25 | Shares Outstanding 36362200 | Shares Floating 10638416 |
Shares Outstanding 36362200 | Shares Floating 10638416 | ||
Percent Insiders 22.16 | Percent Institutions 1.97 |
Upturn AI SWOT
Baird Medical Investment Holdings Limited
Company Overview
History and Background
Baird Medical Investment Holdings Limited is a China-based company focused on the development, manufacturing, and sales of minimally invasive surgical devices and related services. Founded with the aim of providing innovative medical solutions, the company has grown to serve a significant portion of the Chinese market.
Core Business Areas
- Minimally Invasive Surgical Devices: Development, manufacturing, and sales of devices used in minimally invasive surgeries. This includes devices for tumor ablation, diagnostics, and therapeutic procedures.
- Medical Consumables: Production and distribution of consumable products used in conjunction with surgical devices, such as ablation needles and catheters.
- Technical Services: Providing technical support, training, and maintenance services for the company's devices.
Leadership and Structure
The leadership team consists of experienced executives with backgrounds in medical device technology and business management. The company has a structured organizational hierarchy with departments dedicated to R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Microwave Ablation System: Baird Medical's flagship product, used for tumor ablation. The market share is approximately 30% in China. Competitors include Medtronic and Johnson & Johnson. The revenue from this product is significant, though specific numbers are not publicly available.
- Radiofrequency Ablation System: An alternative ablation technology used in a variety of procedures. The market share for this product is approximately 20% in China. Competitors include Boston Scientific and AngioDynamics. The revenue contribution from this product is also substantial, though specific figures are confidential.
Market Dynamics
Industry Overview
The medical device industry in China is experiencing rapid growth due to increasing healthcare expenditures and an aging population. There's a rising demand for minimally invasive surgical procedures.
Positioning
Baird Medical is positioned as a leading domestic player in the Chinese minimally invasive surgical device market. Its competitive advantages include a strong R&D capability, established sales network, and competitive pricing.
Total Addressable Market (TAM)
The TAM for minimally invasive surgical devices in China is estimated to be $5 billion annually. Baird Medical has a strong domestic presence and is well-positioned to capture a significant share of this market. Current market share is around 7.5% (based on the market share on two major products).
Upturn SWOT Analysis
Strengths
- Strong R&D capabilities
- Established sales network in China
- Competitive pricing
- Innovative product portfolio
Weaknesses
- Limited international presence
- Reliance on the Chinese market
- Potential regulatory risks
- Smaller scale compared to global competitors
Opportunities
- Expanding product line
- Entering new geographic markets
- Strategic partnerships and acquisitions
- Increasing healthcare expenditure in China
Threats
- Intense competition
- Changing regulatory landscape
- Pricing pressures
- Economic slowdown
Competitors and Market Share
Key Competitors
- MDT
- JNJ
- BSX
- ANGI
Competitive Landscape
Baird Medical faces strong competition from multinational corporations with greater resources and brand recognition. However, Baird Medical benefits from its local knowledge and competitive pricing.
Growth Trajectory and Initiatives
Historical Growth: Data not available. Baird Medical Investment Holdings Limited is a private company.
Future Projections: Future projections are unavailable due to the company's private status. Analyst estimates are not readily accessible.
Recent Initiatives: Recent initiatives include expanding the product line with new ablation devices and strengthening its distribution network.
Summary
Baird Medical Investment Holdings Limited is a key player in the Chinese minimally invasive surgical device market, driven by its strong R&D and established sales network. While the company benefits from the growing Chinese healthcare market, it faces intense competition from global corporations and relies heavily on its domestic market. Expanding internationally and diversifying its product line are crucial for future growth. The company must navigate regulatory challenges and economic pressures to maintain its competitive edge.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website, industry reports, market analysis
Disclaimers:
Financial data is limited due to the company's private status. Market share data are approximate estimates based on available industry information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Baird Medical Investment Holdings Limited
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2024-10-01 | Chairwoman of the Board of Directors & CEO Ms. Haimei Wu | ||
Sector Healthcare | Industry Medical Devices | Full time employees 143 | Website https://bairdmed.com |
Full time employees 143 | Website https://bairdmed.com | ||
Baird Medical Investment Holdings Limited, together with its subsidiaries, engages in research and development, manufacturing, and sales of microwave ablation and other medical devices in the People's Republic of China. It offers microwave ablation apparatus and needles, as well as microwave ablation apparatus approved for the treatment of live cancer and thyroid nodules, long microwave ablation needles, and fine microwave ablation needles through third-party distributors. Baird Medical Investment Holdings Limited was founded in 2012 and is based in Guangzhou, China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.